PFN1P3: A Potential Drug Target and Biomarker (G200025)

Target Name: PFN1P3

NCBI ID: G200025

PFN1P3

Other Name(s): profilin 1 pseudogene 3 | COAS3 | Profilin 1 pseudogene 3 | COAS-3

PFN1P3: A Potential Drug Target and Biomarker

Profilin 1 pseudogene 3 (PFN1P3) is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and its potential as a drug target or biomarker make it an attractive target for research and development of new treatments.

The PFN1P3 gene is located on chromosome 17 and encodes a protein known as profilin 1. Profilin 1 is a protein that is involved in several cellular processes, including cell adhesion, migration, and invasion. It is a key regulator of the actin-associated protein 2 (PAX) complex, which is involved in the regulation of cell movement and the organization of tissues.

Studies have shown that PFN1P3 is involved in the regulation of several cellular processes that are crucial for the development and progression of cancer. For example, PFN1P3 has been shown to be involved in the regulation of cell proliferation, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

In addition to its role in the regulation of cellular processes, PFN1P3 has also been shown to be involved in the regulation of several signaling pathways that are important for the development of cancer. For example, PFN1P3 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and angiogenesis.

Given its involvement in several cellular processes that are important for the development and progression of cancer, PFN1P3 is an attractive target for drug development. Studies have shown that inhibition of PFN1P3 can lead to the inhibition of the growth and survival of cancer cells. Additionally, inhibition of PFN1P3 has been shown to lead to the regression of established cancer tumors.

In addition to its potential as a drug target, PFN1P3 is also a potential biomarker for several diseases. The expression of PFN1P3 has been shown to be associated with the development of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, PFN1P3 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In conclusion, PFN1P3 is a gene that has been identified as a potential drug target or biomarker for several diseases. Its unique function and its potential as a drug target or biomarker make it an attractive target for research and development of new treatments. Further studies are needed to fully understand the role of PFN1P3 in the development and progression of cancer and other diseases.

Protein Name: Profilin 1 Pseudogene 3

The "PFN1P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PFN1P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets